Condition

Small Cell Lung Cancer (SCLC)

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 35 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials35
Recruiting15
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

35 shown
Safety and Preliminary Activity of BI115 in Advanced SCLCNCT07559019 · 2026-05-21
RECRUITING
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479 · 2026-05-18
RECRUITING
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198 · 2026-04-13
RECRUITING
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)NCT07744256 · 2026-03-02
RECRUITING
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerNCT07149363 · 2026-02-12
RECRUITING
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)NCT07480213 · 2026-02-02
RECRUITING
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerNCT07358676 · 2026-02-01
RECRUITING
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLCNCT07434518 · 2026-01-27
RECRUITING
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor TislelizumabNCT07510724 · 2025-12-23
RECRUITING
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999 · 2025-12-09
RECRUITING
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07
RECRUITING
THE-0504 in Patients With Solid TumorsNCT07646106 · 2024-11-13
RECRUITING
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized TrialNCT06485544 · 2024-07-01
RECRUITING
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)NCT05652686 · 2023-09-05
RECRUITING
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977 · 2018-04-17
RECRUITING
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323 · 2025-02-26
ACTIVE_NOT_RECRUITING
Sarcopenia and Cachexia in Patients With Lung CancerNCT06730685 · 2024-12-12
ENROLLING_BY_INVITATION
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31
ACTIVE_NOT_RECRUITING
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLCNCT05158491 · 2021-11-11
UNKNOWN
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLCNCT05027100 · 2021-09-30
UNKNOWN
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)NCT04727853 · 2021-03-01
COMPLETED
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.NCT04285866 · 2020-05-21
COMPLETED
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsNCT03811652 · 2018-12-20
COMPLETED
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsNCT03708328 · 2018-10-15
COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesNCT03538028 · 2018-06-18
COMPLETED
Pembrolizumab in Untreated Extensive SCLCNCT02580994 · 2017-12-08
COMPLETED
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine CarcinomasNCT02030184 · 2017-06-01
WITHDRAWN
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)NCT03066778 · 2017-05-02
COMPLETED
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)NCT02934503 · 2017-01-23
TERMINATED
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell CancerNCT02769832 · 2016-08-29
COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)NCT02628067 · 2015-12-18
ACTIVE_NOT_RECRUITING
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid TumorNCT02069158 · 2014-04-01
COMPLETED
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyNCT01904253 · 2013-07-01
TERMINATED
Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)NCT01210131 · 2013-07-01
WITHDRAWN
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine TumorsNCT01719861 · 2012-10-01
TERMINATED

Common interventions

Trial status mix

RECRUITING15
COMPLETED9
ACTIVE_NOT_RECRUITING3
TERMINATED3
UNKNOWN2
WITHDRAWN2
ENROLLING_BY_INVITATION1

Phase mix

PHASE218
PHASE114
PHASE34
NA2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.